Pancreatic amylin as a centrally acting satiating hormone.
about
Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight LossObesity pharmacotherapy: current perspectives and future directionsTopical review: a comprehensive risk model for disordered eating in youth with type 1 diabetesAmylin at the interface between metabolic and neurodegenerative disordersAmylin modulates the mesolimbic dopamine system to control energy balance.Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive PotentialChanges in neurohormonal gut peptides following bariatric surgery.Brain imaging studies of appetite in the context of obesity and the menstrual cycle.Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classificationCentral amylin acts as an adiposity signal to control body weight and energy expenditureEmerging pharmacotherapy for obesity.Ghrelin action in the brain controls adipocyte metabolismModulation of appetite by gonadal steroid hormones.Pancreatic signals controlling food intake; insulin, glucagon and amylinRole of gastrointestinal hormones in feeding behavior and obesity treatment.Potential use of exenatide for the treatment of obesity.Hypoglycemic Effect of Laminaria japonica Polysaccharide in a Type 2 Diabetes Mellitus Mouse Model.Hunger and satiety: one brain for two?Appetite and body weight regulation after bariatric surgery.Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.Eating in mice with gastric bypass surgery causes exaggerated activation of brainstem anorexia circuit.Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.Control of food intake and energy expenditure by amylin-therapeutic implications.Pharmacological management of appetite expression in obesity.Peptides and food intake.New drug targets for the treatment of obesity.Role of Amylin in Type 1 and Type 2 Diabetes.Amylin-mediated control of glycemia, energy balance, and cognition.Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity.Amylin modulates the formalin-induced tonic pain behaviours in rats.Noradrenergic neurons of the area postrema mediate amylin's hypophagic action.Food intake and meal pattern in IAPP knockout mice with and without infusion of exogenous IAPP.Differential responses of circulating amylin to high-fat vs. high-carbohydrate meal in healthy men.Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.Examination of Psychosocial and Physiological Risk for Bulimic Symptoms in Youth With Type 1 Diabetes Transitioning to an Insulin Pump: A Pilot Study.Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.GABAA receptor antagonists prevent abnormalities in leptin, insulin and amylin actions on paraventricular hypothalamic neurons of overweight rats.Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect.
P2860
Q26741066-17B956E9-EE7A-4377-A700-17863C47EFC6Q26828559-EF730D7A-A67E-4F5D-8301-91D72876E5DDQ26865946-A8F99923-BA7D-4D6F-998B-C26848AF701FQ27003342-8EADD9F6-605C-405C-A0C8-BD86EE14C48DQ27311258-D6B24B1E-3EE2-4C2D-899B-218B884D50CEQ29994589-129C3F75-1113-452B-8B18-165237474E8FQ30391329-65739BE9-A361-45A0-829C-13C5ECA411ECQ33516301-E33A10BE-4AC3-4184-A667-975EFFFB9A89Q33683839-996A88BA-A26D-48EF-9954-54E5CBD5F6E7Q33976258-4681B387-BF57-47FC-81D2-B304E1C9146AQ34207458-7E176A2D-9DA6-438D-97E6-B1C245DD6C1AQ34661800-551A4222-85B8-4631-B826-35CA1EECD260Q35140236-1C13DD82-2BC9-4B71-8E3C-9DA91D0C45C6Q35140241-3762BA0B-AC11-420B-9D05-9083E37147D2Q35766237-F5C41574-3616-45B0-AB8D-CA9D9F7D0270Q36391466-50D54DA6-9948-470B-9AB5-818AFBEF9CDDQ36415167-99E54E83-3AFD-4C89-8AD1-16738B0D98A8Q36508186-E4C0585C-6A4D-4843-9FC1-D666A96C8706Q36669384-B250FC95-C81D-445E-8214-1064527A2236Q36842060-E65F584F-BEE2-4CE3-AD2E-922BED10CCFDQ36984713-803CA811-2A29-4733-AA23-0FD80B1A64DBQ37319183-3BB4EE5D-32FC-4984-BEE0-5DCF2A00C884Q37368085-0003B599-AD36-4D6F-BAAD-1993B3F85EB8Q37442584-D036B4F0-626C-4A7A-96D9-9A9D219D54CDQ37710372-79766850-FB59-486E-A827-A13DD039829FQ37734840-07A04666-6752-4CB0-8A19-337D4F5CD0E2Q37886661-D83413E7-C1DB-45D8-9653-81E6BEABBF11Q38596374-5D8D9E10-8FCB-47A9-96A5-C2E5237AB026Q38753342-566C3F47-CD3F-4237-99E0-7F9E757CBEDFQ38759289-A1078689-273C-45DF-AC0E-4EB2B992ED2BQ39449063-71917C1F-D1EA-4A7D-B7E7-29D29FF442EAQ39708728-F2CE77D8-6BFA-46E9-AA9B-396280D85123Q43016753-0446CF33-0881-4309-92F0-916058F31633Q43866304-E939F972-A45B-4220-B3C8-8919296E601CQ46887483-FAAF5061-E973-4C83-BA94-D0A1CD4B74C6Q47288853-767E662D-1B84-450B-BE90-76373FED1C77Q47755659-B71C13E0-253E-4B73-B20B-7E26BB55920DQ48400779-446E2F66-D58D-41B3-BD80-B69DF607DBD0Q48608888-C4B19A4C-3625-45FF-A896-69D74AA7D493Q51364602-8419E97E-55D4-4400-8739-9DECCECCC2E1
P2860
Pancreatic amylin as a centrally acting satiating hormone.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pancreatic amylin as a centrally acting satiating hormone.
@ast
Pancreatic amylin as a centrally acting satiating hormone.
@en
type
label
Pancreatic amylin as a centrally acting satiating hormone.
@ast
Pancreatic amylin as a centrally acting satiating hormone.
@en
prefLabel
Pancreatic amylin as a centrally acting satiating hormone.
@ast
Pancreatic amylin as a centrally acting satiating hormone.
@en
P356
P1433
P1476
Pancreatic amylin as a centrally acting satiating hormone.
@en
P2093
Thomas A Lutz
P304
P356
10.2174/1389450053174596
P577
2005-03-01T00:00:00Z